Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06527456

Intervention With General Practitioners to Improve Women's Participation in Cervical Cancer Screening

In France, cervical cancer is the 12th most common female cancer with nearly 3,000 new cases per year.

Since 2018, a national Organized Cervical Cancer Screening program (DOCCU) has been set up and concerns all asymptomatic women aged 25 to 65.

This program, managed by the Regional Cancer Screening Coordination Centers (CRCDC), invites women who have not taken a sample within the recommended time frame to consult for screening. However, only 59% of patients participated.

The intervention of the general practitioner, an essential player in prevention, could allow for better awareness.

The objective of the INDIGO study is to evaluate the effectiveness of the intervention of a general practitioner on the participation rate in the DOCCU of patients who are not up to date with their screening.

Recruiting

Interested in participating?

Request Info

Key information

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Médecins généralistes dans le bassin de l'UPEC

Créteil, France

Location status: Recruiting

Location contact

Emilie FERRAT, phD

CONTACT

[email protected]

About this study

This is a cluster-randomized trial. Randomization will be performed at the GP practice level to limit the potential contamination bias between doctors within the same practice. GP practices will be randomized either to the 'usual practice' arm or the 'intervention' arm."

If they are in the "intervention" group, they or one of the professionals in their team will contact the patient (phone call, SMS, email, etc.), to encourage her to make an appointment to carry out the screening. Contact arrangements are left to the discretion of each general practitioner..

If they are in the "Usual practice" group, they will use their usual practices to encourage screening.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Woman aged 25 to 65 living in Ile-De-France
  • Eligible for DOCCU (not hysterectomized, not followed for a pre-cancerous or cancerous lesion of the cervix)
  • Having declared the investigating general practitioner as a treating physician (MT) and whose MT practices in the territory of a CPTS in the UPEC area
  • Affiliate to a social security scheme or beneficiary of such a scheme

Exclusion criteria

  • Patient already included in a study on DOCCU
  • Patient excluded from organized screening (cervical cancer, hysterectomy).
  • Patient's opposition to participating in the study

Treatment and study plan

participation of the general practitioner

Other

participation of the general practitioner in encouraging cervical cancer screening

Primary outcomes

  1. screening participation rate

    Time frame: 12 month

    percentage of patients who had a screening Cervical Sample (cytology or HPV test within a timeframe satisfying the HAS recommendations according to age) among patients eligible for screening aged 25 to 65 years

Study contacts

Contact information is provided by the study sponsor or research team.

Camille JUNG

CONTACT

[email protected]

01.57.02.22.68

Emilie FERRAT

CONTACT

[email protected]

0633085225

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Intercommunal Creteil

Other

Registry information

Acronym: INDIGO

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 30, 2024
Registry last updated
Apr 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.